Feasibility chart review for Mulitcentre, randomized, double blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, a

  • Willis, Maurice (PI)

    Project: Other project

    Project Details

    Effective start/end date6/17/146/16/16


    • Parexel International: $592.31